Equity Profile

TGTX

TG THERAPEUTICS INC

Health CareBiotechnology$6.1B

May6Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

TG Therapeutics Misses on EPS, Stock Up 16.26%

Metric	Actual	Expected	Surprise
EPS	$0.12	N/A	-48.50%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

TG Therapeutics Misses on EPS, Stock Up 16.26%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.12	N/A	-48.50%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

TG Therapeutics reported an EPS of $0.12, which was below expectations, resulting in a significant stock increase of 16.26%. This reaction may indicate investor optimism despite the earnings miss. The lack of revenue data and guidance leaves some uncertainty about future performance.

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and commercial success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs with novel treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

In the last quarter, TG Therapeutics reported an EPS of $0.14, which was significantly below the estimated $0.35, resulting in a 60.45% surprise to the downside. The stock reacted positively the next day, gaining 4.18%.

Management Promises & Guidance

Focus on advancing clinical trials for pipeline products.
Commitment to improving operational efficiencies.
Plans to enhance communication with investors regarding future strategies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors will be keen to see if the company can turn around its recent performance.

Bull Case

If TG Therapeutics can deliver strong clinical trial results and exceed EPS expectations, it could signal a turnaround and boost investor confidence.

Bear Case

On the other hand, if the company continues to miss EPS estimates and fails to provide clear guidance on its pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the company's recent history of missing EPS estimates, this figure will be crucial in determining market sentiment.

What updates can management provide on the progress of clinical trials?

Investors are particularly interested in the success of clinical trials, as this can significantly impact the company's future growth and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to surprise on the upside with its clinical trial results, which have shown promise in preliminary stages.

Supporting Evidence

The company's recent focus on operational improvements may yield better-than-expected results.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.

The positive reaction to the last quarter's results, despite a miss, shows underlying investor interest.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as the company seeks to regain investor confidence after a series of disappointing earnings.

Bull Confirmed If

A positive EPS surprise of at least 15% would confirm the bull case and suggest improving operational performance.

Bear Confirmed If

An EPS miss of more than 20% would reinforce the bear case and raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±9.48%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

41.8%

Calls (78K)P/C Ratio: 2.48Puts (16K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests the stock could rise by an average of 10.28%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 4.05%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Specific EPS guidance for the upcoming quarter.
2Updates on the status and results of ongoing clinical trials.
3Management's outlook on market conditions and competitive landscape.
4Any changes to the company's strategic priorities or operational focus.
5Insights into potential partnerships or collaborations in the pipeline.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and commercial success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for pipeline products.
Commitment to improving operational efficiencies.
Plans to enhance communication with investors regarding future strategies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors will be keen to see if the company can turn around its recent performance.

Bull Case

If TG Therapeutics can deliver strong clinical trial results and exceed EPS expectations, it could signal a turnaround and boost investor confidence.

Bear Case

On the other hand, if the company continues to miss EPS estimates and fails to provide clear guidance on its pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the company's recent history of missing EPS estimates, this figure will be crucial in determining market sentiment.

What updates can management provide on the progress of clinical trials?

Investors are particularly interested in the success of clinical trials, as this can significantly impact the company's future growth and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to surprise on the upside with its clinical trial results, which have shown promise in preliminary stages.

Supporting Evidence

The company's recent focus on operational improvements may yield better-than-expected results.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.

The positive reaction to the last quarter's results, despite a miss, shows underlying investor interest.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as the company seeks to regain investor confidence after a series of disappointing earnings.

Bull Confirmed If

A positive EPS surprise of at least 15% would confirm the bull case and suggest improving operational performance.

Bear Confirmed If

An EPS miss of more than 20% would reinforce the bear case and raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±9.48%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

41.8%

Calls (78K)P/C Ratio: 2.48Puts (16K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests the stock could rise by an average of 10.28%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 4.05%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Specific EPS guidance for the upcoming quarter.
2Updates on the status and results of ongoing clinical trials.
3Management's outlook on market conditions and competitive landscape.
4Any changes to the company's strategic priorities or operational focus.
5Insights into potential partnerships or collaborations in the pipeline.